Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients

OBJECTIVES: Recent studies showed prolonged survival for advanced epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) patients treated with both monotherapies and combined therapies. However, high costs limit clinical applications. Thus, we conducted this cost‐effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wen‐Qian, Li, Ling‐Yu, Chai, Jin, Cui, Jiu‐Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957173/
https://www.ncbi.nlm.nih.gov/pubmed/33626238
http://dx.doi.org/10.1002/cam4.3733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957173/
https://www.ncbi.nlm.nih.gov/pubmed/33626238
http://dx.doi.org/10.1002/cam4.3733

Ejemplares similares